Nexus Surgical

Who are in the management team of Nexus Surgical?

As of March 2023, the management team of Nexus Surgical includes Ram Swaroop Mahadev Joshi (Whole Time Director & CFO), Pawan Choudhary (Executive Director), and three Independent Non-Executive Directors: Rajesh Sodhani, Avinash Kumar Ardawatia, and Neha Kailash Bhageria.

As of March 2023, the management team of Nexus Surgical includes the following individuals:<BR><BR>1. Ram Swaroop Mahadev Joshi - Whole Time Director & CFO<BR>2. Pawan Choudhary - Executive Director<BR>3. Rajesh Sodhani - Independent Non-Executive Director<BR>4. Avinash Kumar Ardawatia - Independent Non-Executive Director<BR>5. Neha Kailash Bhageria - Independent Non-Executive Director<BR><BR>These members play various roles within the company's governance and management structure.

What does Nexus Surgical do?

Nexus Surgical and Medicare Ltd trades in medical essentials and operates as a Micro Cap NBFC. As of March 2025, it reported net sales of 1 Cr and a market cap of Rs 9 Cr, with a P/E ratio of 9.00.

Overview:<BR>Nexus Surgical and Medicare Ltd is engaged in the trading of medical essentials and operates within the Non Banking Financial Company (NBFC) industry, categorized as a Micro Cap.<BR><BR>History:<BR>Incorporated in 1992, Nexus Surgical and Medicare Ltd was formerly known as Nexus Commodities and Technologies Ltd. The company has undergone a status change and is currently reporting its financial results for the quarter ending March 2025, with net sales and profit figures available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 9.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 47.17% <BR>Price to Book: 8.86 <BR><BR>Contact Details:<BR>Address: Gala No 4 Saarthak Bldg No 1, Square Industrial Park Palghar Maharashtra : 401208 <BR>Email: nexuscom99@gmail.com <BR>Website: http://www.nexusmed.co.in

Has Nexus Surgical declared dividend?

No Dividend History Available

Who are the peers of the Nexus Surgical?

Nexus Surgical's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Prism Medico, Trinity League, and BCL Enterprises. Bajaj Finance leads in returns and management quality, while Nexus Surgical shows average growth and a 1-year return of 6.45%.

Peers: The peers of Nexus Surgical are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Prism Medico, Trinity League, and BCL Enterprises.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial, Nexus Surgical, BCL Enterprises, and the rest. Good growth is noted at Bajaj Finance, Cholaman.Inv.&Fn, Shriram Finance, and BCL Enterprises, while Average growth is seen at Nexus Surgical, Jio Financial, Muthoot Finance, and the rest. Excellent capital structure is present at Bajaj Finance, Shriram Finance, Muthoot Finance, and BCL Enterprises, while Good capital structure is observed at Cholaman.Inv.&Fn, and Average capital structure is found at Trinity League, with Libord Securitie and Prism Medico not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bajaj Finance at 30.41%, while the lowest is Jio Financial at -20.22%. Nexus Surgical's 1-year return is 6.45%, which is higher than Jio Financial but lower than Bajaj Finance. Additionally, Libord Securitie, Prism Medico, Trinity League, and BCL Enterprises have negative six-month returns.

Is Nexus Surgical overvalued or undervalued?

As of November 15, 2023, Nexus Surgical is considered very expensive and overvalued with a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a high ROE of 47.17%, but it has underperformed the Sensex by 37.39% year-to-date.

As of 15 November 2023, Nexus Surgical's valuation grade has moved from risky to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 9.23, an EV to EBIT ratio of 8.90, and a ROE of 47.17%. These figures suggest that while the company has a high return on equity, its valuation metrics are not compelling when compared to peers.<BR><BR>In comparison to its industry peers, Nexus Surgical's PE ratio of 9.23 is lower than Life Insurance's PE of 12.54, but significantly higher than Bajaj Finance's PE of 35.01, which is categorized as very expensive. The PEG ratio of 0.07 also highlights that the stock may not be justified at its current price given its growth prospects. Additionally, Nexus Surgical has underperformed the Sensex over various time frames, particularly year-to-date, where it has declined by 37.39% compared to the Sensex's gain of 5.59%.

What is the technical trend for Nexus Surgical?

As of June 4, 2025, Nexus Surgical's trend is mildly bearish due to daily moving averages, despite mixed signals from weekly and monthly indicators, with the stock down 6.39% over the past week.

As of 4 June 2025, the technical trend for Nexus Surgical has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. The weekly MACD and KST are mildly bullish, but the monthly MACD and KST are mildly bearish, suggesting mixed signals across different time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, but this is overshadowed by the bearish daily moving averages. Overall, the strength of the bearish trend is supported by the recent price action, with the stock down 6.39% over the past week, contrasting with a positive return from the Sensex.

Who are the top shareholders of the Nexus Surgical?

The top shareholders of Nexus Surgical are Mildred Mercantile Private Limited with 18.55%, Harivardhan Steel & Alloys Private Limited at 16.01%, and individual investors holding a combined 44.64%. There are no institutional holdings in the company.

The top shareholders of Nexus Surgical include Mildred Mercantile Private Limited, which holds the highest promoter stake at 18.55%. The next significant public shareholder is Harivardhan Steel & Alloys Private Limited, with a holding of 16.01%. Additionally, individual investors collectively hold 44.64% of the company's shares. There are no institutional holdings reported, as mutual funds and foreign institutional investors do not hold any shares in Nexus Surgical.

How big is Nexus Surgical?

As of 24th July, Nexus Surgical and Medicare Ltd has a market capitalization of 9.00 Cr, with recent net sales of 5.71 Cr and a net profit of 0.50 Cr. The balance sheet for March 2024 shows shareholder's funds of 0.57 Cr and total assets of 1.80 Cr.

As of 24th July, Nexus Surgical and Medicare Ltd has a market capitalization of 9.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 5.71 Cr and a Net Profit of 0.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 0.57 Cr and Total Assets of 1.80 Cr.

How has been the historical performance of Nexus Surgical?

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.

Answer:<BR>The historical performance of Nexus Surgical shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Nexus Surgical's net sales have increased from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, indicating strong growth. Total operating income followed a similar trend, rising from 1.55 Cr in March 2023 to 5.72 Cr in March 2025. The company's total expenditure also grew, reaching 5.06 Cr in March 2025, up from 1.34 Cr in March 2023. Despite this increase, the operating profit (PBDIT) improved from 0.21 Cr in March 2023 to 0.67 Cr in March 2025, reflecting a healthier operating profit margin of 11.54% in March 2025 compared to 13.55% in March 2023. Profit before tax also rose from 0.23 Cr in March 2023 to 0.67 Cr in March 2025, with profit after tax increasing from 0.17 Cr to 0.50 Cr over the same period. The earnings per share (EPS) improved significantly from 0.31 in March 2023 to 0.91 in March 2025. On the balance sheet, total assets increased from 0.91 Cr in March 2023 to 2.27 Cr in March 2025, while total liabilities rose from 0.91 Cr to 2.27 Cr in the same timeframe. The company has maintained zero debt throughout this period. Overall, Nexus Surgical's financial performance demonstrates a positive trajectory in sales, profitability, and asset growth.

When is the next results date for Nexus Surgical and Medicare Ltd?

The next results date for Nexus Surgical and Medicare Ltd is 14 February 2026.

The next results date for Nexus Surgical and Medicare Ltd is scheduled for 14 February 2026.

Are Nexus Surgical and Medicare Ltd latest results good or bad?

Nexus Surgical's latest results are mixed; while net profit increased and operating margins improved, revenue fell sharply by 32.37% quarter-over-quarter, raising concerns about stability and sustainability due to a fragile balance sheet and low institutional support. Investors should exercise caution.

The latest results for Nexus Surgical present a mixed picture. On one hand, the company achieved a net profit of ₹0.17 crores in Q2 FY26, which is a 13.33% increase compared to the previous quarter. Additionally, the operating margin improved significantly to 20.51%, up from 12.14% in Q1 FY26, indicating better efficiency in managing costs.<BR><BR>However, the revenue for the same quarter fell sharply by 32.37% quarter-over-quarter, dropping to ₹1.17 crores from ₹1.73 crores. While there was an 18.18% increase in revenue compared to the same quarter last year, the recent quarter's decline raises concerns about the stability of the company's revenue stream.<BR><BR>Moreover, the company's balance sheet shows fragility, with minimal equity and accumulated losses, which could pose risks for future sustainability. The lack of institutional backing and low promoter holding further complicate its outlook.<BR><BR>In summary, while the profitability margins have improved, the significant revenue decline and underlying financial weaknesses suggest that the overall results are concerning. Investors should be cautious given the volatility and risks associated with Nexus Surgical.

Should I buy, sell or hold Nexus Surgical and Medicare Ltd?

Which are the latest news on Nexus Surgical?

Why is Nexus Surgical and Medicare Ltd falling/rising?

As of 20-May, Nexus Surgical and Medicare Ltd's stock price is rising due to recent performance gains, with a current price of 20.01 and a year-to-date increase of 14.34%, despite a significant drop in investor participation.

As of 20-May, Nexus Surgical and Medicare Ltd's stock price is rising, currently at 20.01, with a change of 0.95, representing an increase of 4.98%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.97% today and has experienced consecutive gains over the last two days, accumulating a total return of 5.32% during this period. <BR><BR>Additionally, the stock's year-to-date performance shows a significant increase of 14.34%, contrasting with a decline of 11.62% in the benchmark Sensex, indicating strong relative strength. Over the past year, the stock has also risen by 16.00%, further demonstrating its positive trajectory compared to the broader market.<BR><BR>However, it is worth noting that while the stock is currently rising, there has been a notable decline in investor participation, with delivery volume dropping by 81.82% against the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading, as it is based on 2% of the 5-day average traded value.<BR><BR>In summary, the combination of recent performance gains, strong year-to-date returns, and relative outperformance against the sector contributes to the rising stock price of Nexus Surgical and Medicare Ltd.